AZN

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...
Search

Funds

AZN

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...
Search

Funds

AZN

FTSE 100

Funds